The role of imaging in the staging, treatment planning, and ongoing surveillance of
patients with head and neck squamous cell carcinoma (HNSCC) continues to evolve. Changes in
patient demographics, treatment paradigms, and technology present opportunities and
challenges for the management of HNSCC.
Methods
The general indications and usage of standard and multimodal cross-sectional imaging in the
evaluation and management of HNSCC are reviewed, with an emphasis on incorporating them into
treatment pathways. Emerging imaging technologies and methods with a potential near-term
impact on HNSCC are discussed.
Results
In general, the complex, multidisciplinary approach to the treatment of advanced HNSCC
requires multimodal imaging for adequate treatment planning and follow up. Early-stage
disease can often be managed with clinical and endoscopic examinations and a single,
cross-sectional imaging modality (eg, computed tomography, magnetic resonance imaging).
Conclusions
Although generalized treatment pathways and guidelines do exist, the literature is rapidly
advancing and new radiotracers and evaluation methods are expected to alter both imaging and
treatment recommendations in the years to come.
StewartB.W.,
WildC., eds. World
Cancer Report.Lyon, France: International Agency for
Research on Cancer; World Health Organization;
2014.
3.
DeschlerD.G.,
RichmonJ.D.,
KhariwalaS.S.The “new-head and neck cancer patient-young, nonsmoker, nondrinker, and HPV
positive: evaluation.Otolaryngol Head Neck Surg.2014; 151(3):
375–380.
EdgeS.,
ByrdD.R.,
ComptonC.C.AJCC Cancer Staging Manual.7th ed.New York: Springer;
2010.
6.
RumboldtZ.,
GordonL.,
BonsallR.Imaging in head and neck cancer.Curr Treat Options Oncol.2006; 7(1):
23–34.
7.
EscottE.J.Role of positron emission tomography/computed tomography (PET/CT) in head
and neck cancer.Radiol Clin North Am.2013; 51(5):
881–893.
8.
CorryJ.,
RischinD.,
HicksR.J.The role of PET-CT in the management of patients with advanced cancer of
the head and neck.Curr Oncol Rep.2008; 10(2):
149–155.
9.
SpectorM.E.,
GallagherK.K.,
LightE.Matted nodes: poor prognostic marker in oropharyngeal squamous cell
carcinoma independent of HPV and EGFR status.Head Neck.2012; 34(12):
1727–1733.
10.
SpectorM.E.,
ChinnS.B.,
BellileE.Matted nodes as a predictor of distant metastasis in advanced-stage III/IV
oropharyngeal squamous cell carcinoma.Head Neck.2016; 38(2):
184–190.
11.
SomP.M.Detection of metastasis in cervical lymph nodes: CT and MR criteria and
differential diagnosis.AJR Am J Roentgenol.1992; 158(5):
961–969.
12.
SubramaniamR.M.,
AlluriK.C.,
TahariA.K.PET/CT imaging and human papilloma virus-positive oropharyngeal squamous
cell cancer: evolving clinical imaging paradigm.J Nucl Med.2014; 55(3):
431–438.
13.
YamazakiY.,
SaitohM.,
NotaniK.Assessment of cervical lymph node metastases using FDG-PET in patients with
head and neck cancer.Ann Nucl Med.2008; 22(3):
177–184.
14.
FerlitoA.,
ShahaA.R.,
SilverC.E.Incidence and sites of distant metastases from head and neck
cancer.ORL J Otorhinolaryngol Relat Spec.2001; 63(4):
202–207.
15.
NgS.H.,
ChanS.C.,
LiaoC.T.Distant metastases and synchronous second primary tumors in patients with
newly diagnosed oropharyn-geal and hypopharyngeal carcinomas: evaluation of (18)F-FDG
PET and extended-field multi-detector row CT.Neuroradiology.2008; 50(11):
969–979.
16.
XuG.Z.,
GuanD.J.,
HeZ.Y.(18)FDG-PET/CT for detecting distant metastases and second primary cancers
in patients with head and neck cancer. A meta-analysis.Oral Oncol.2011; 47(7):
560–565.
17.
IssingW.J.,
TalebanB.,
TauberS.Diagnosis and management of carcinoma of unknown primary in the head and
neck.Eur Arch Otorhino-laryngol.2003; 260(8):
436–443.
18.
StrojanP.,
FerlitoA.,
MedinaJ.E.Contemporary management of lymph node metastases from an unknown primary to
the neck: I. A review of diagnostic approaches.Head Neck.2013; 35(1):
123–132.
19.
MotzK.,
QualliotineJ.R.,
RettigE.Changes in unknown primary squamous cell carcinoma of the head and neck at
initial presentation in the era of human papillomavirus.JAMA Otolaryngol Head Neck Surg.2016; 142(3):
223–238.
20.
LeeJ.R.,
KimJ.S.,
RohJ.L.Detection of occult primary tumors in patients with cervical metastases of
unknown primary tumors: comparison of (18)F FDG PET/CT with contrast-enhanced CT or
CT/MR imaging-prospective study.Radiology.2015; 274(3):
764–771.
21.
HermansR.Imaging in cervical nodal metastases of unknown primary.Cancer Imaging.2011; 11(A):
S9–S14.
22.
FletcherJ.W.,
DjulbegovicB.,
SoaresH.P.Recommendations on the use of 18F-FDG PET in oncology.J Nucl Med.2008; 49(3):
480–508.
23.
KochW.M.,
BhattiN.,
WilliamsM.F.Oncologic rationale for bilateral tonsillectomy in head and neck squamous
cell carcinoma of unknown primary source.Otolaryngol Head Neck Surg.2001; 124(3):
331–333.
24.
KothariP.,
RandhawaP.S.,
FarrellR.Role of tonsillectomy in the search for a squamous cell carcinoma from an
unknown primary in the head and neck.Br J Oral Maxillofac Surg.2008; 46(4):
283–237.
25.
NahmiasC.,
CarlsonE.R.,
DuncanL.D.Positron emission tomography/computerized tomography (PET/CT) scanning for
preoper-ative staging of patients with oral/head and neck cancer.J Oral Maxillofac Surg.2007; 65(12):
2524–2535.
26.
NgS.H.,
YenT.C.,
ChangJ.T.Prospective study of [18F]fluorode-oxyglucose positron emission tomography
and computed tomography and magnetic resonance imaging in oral cavity squamous cell
carcinoma with palpably negative neck.J Clin Oncol.2006; 24(27):
4371–4376.
27.
SchöderH.,
CarlsonD.L.,
KrausD.H.18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer
staged N0 by clinical examination and CT/MRI.J Nucl Med.2006; 47(5):
755–762.
28.
SchroederU.,
DietleinM.,
WittekindtC.Is there a need for positron emission tomography imaging to stage the N0
neck in T1-T2 squamous cell carcinoma of the oral cavity or oropharynx?Ann Otol Rhinol Laryngol.2008; 117(11):
854–863.
29.
LiaoL.J.,
LoW.C.,
HsuW.L.Detection of cervical lymph node metastasis in head and neck cancer
patients with clinically N0 neck-a metaanalysis comparing different imaging
modalities.BMC Cancer.2012; 12: 236.
30.
RohJ.L.,
ParkJ.P.,
KimJ.S.18F fluorodeoxyglucose PET/CT in head and neck squamous cell carcinoma with
negative neck palpation findings: a prospective study.Radiology.2014; 271(1):
153–161.
31.
BranstetterB.F.,
BlodgettT.M.,
ZimmerL.A.Head and neck malignancy: is PET/CT more accurate than PET or CT
alone?Radiology.2005; 235(2):
580–586.
32.
BirkelandA.C.,
RoskoA.J.,
ChinnS.B.Prevalence and outcomes of head and neck versus non-head and neck second
primary malignancies in head and neck squamous cell carcinoma: an analysis of the
Surveillance, Epidemiology, and End Results database.ORL J Otorhinolaryngol Relat Spec.2016; 78(2):
61–69.
33.
ChanS.C.,
WangH.M.,
YenT.C.18F-FDG PET/CT and 3.0-T whole-body MRI for the detection of distant
metastases and second primary tumours in patients with untreated
oropharyngeal/hypopharyngeal carcinoma: a comparative study.Eur J Nucl Med Mol Imaging.2011; 38(9):
1607–1619.
34.
FukuiM.B.,
BlodgettT.M.,
SnydermanC.H.Combined PET-CT in the head and neck: part 2. Diagnostic uses and pitfalls
of oncologic imaging.Radiographics.2005; 25(4):
913–930.
35.
KingK.G.,
KositwattanarerkA.,
GendenE.Cancers of the oral cavity and oropharynx: FDG PET with contrast-enhanced
CT in the posttreatment setting.Radiographics.2011; 31(2):
355–373.
36.
GaoS.,
LiS.,
YangX.,
TangQ.18FDG PET-CT for distant metastases in patients with recurrent head and
neck cancer after definitive treatment. A meta-analysis.Oral Oncol.2014; 50(3):
163–167.
37.
NgS.H.,
ChanS.C.,
YenT.C.PET/CT and 3-T whole-body MRI in the detection of malignancy in treated
oropharyngeal and hypopharyngeal carcinoma.Eur J Nucl Med Mol Imaging.2011; 38(6):
996–1008.
38.
KoyasuS.,
NakamotoY.,
KikuchiM.Prognostic value of pre-treatment 18F-FDG PET/CT parameters including
visual evaluation in patients with head and neck squamous cell
carcinoma.AJR Am J Roentgenol.2014; 202(4):
851–858.
39.
ChungM.K.,
JeongH.S.,
SonY.I.Metabolic tumor volumes by [18F]-fluorodeoxyglucose PET/CT correlate with
occult metastasis in oral squamous cell carcinoma of the tongue.Ann Surg Oncol.2009; 16(11):
3111–3117.
40.
AertsH.J.,
VelazquezE.R.,
LeijenaarR.T.Decoding tumour phenotype by noninvasive imaging using a quantitative
radiomics approach.Nat Commun.2014; 5: 4006.
41.
LeijenaarR.T.,
CarvalhoS.,
HoebersF.J.External validation of a prognostic CT-based radiomic signature in
oropharyngeal squamous cell carcinoma.Acta Oncol.2015; 54(9):
1423–1429.
42.
GatenbyR.A.,
GilliesR.J.Why do cancers have high aerobic glycolysis?Nat Rev Cancer.2004; 4(11):
891–899.
43.
HoshikawaH.,
YamamotoY.,
MoriT.Predictive value of SUV-based parameters derived from pre-treatment
(18)F-FLT PET/CT for short-term outcome with head and neck cancers.Ann Nucl Med.2014; 28(10):
1020–1026.
44.
van
DijkL.K.,
BoermanO.C.,
KaandersJ.H.PET imaging in head and neck cancer patients to monitor treatment response:
a future role for EGFR-targeted imaging.Clin Cancer Res.2015; 21(16):
3602–3609.
45.
ZschaeckS.,
HaaseR.,
AbolmaaliN.Spatial distribution of FMISO in head and neck squamous cell carcinomas
during radio-chemotherapy and its correlation to pattern of failure.Acta Oncol.2015; 54(9):
1355–1363.
